Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYTOCHROME P4502D6' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 29 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Siegle, I; Fritz, P; Eckhardt, K; Zanger, UM; Eichelbaum, M
      Cellular localization and regional distribution of CYP2D6 mRNA and proteinexpression in human brain

      PHARMACOGENETICS
    2. Ma, Y; Fracanzani, AL; Sampietro, M; Mattioli, M; Cheeseman, P; Williams, R; Mieli-Vergani, G; Vergani, D; Fargion, S
      Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda

      CLINICAL AND EXPERIMENTAL IMMUNOLOGY
    3. Muratori, L; Parola, M; Ripalti, A; Robino, G; Muratori, P; Bellomo, G; Carini, R; Lenzi, M; Landini, MP; Albano, E; Bianchi, FB
      Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane

      GUT
    4. Hemeryck, A; Lefebvre, RA; De Vriendt, C; Belpaire, FM
      Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    5. Leucht, S; Hackl, HJ; Steimer, W; Angersbach, D; Zimmer, R
      Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients

      PSYCHOPHARMACOLOGY
    6. Ekins, S; Bravi, G; Binkley, S; Gillespie, JS; Ring, BJ; Wikel, JH; Wrighton, SA
      Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors

      PHARMACOGENETICS
    7. Miyakawa, H; Kikazawa, E; Abe, K; Kikuchi, K; Fujikawa, H; Matsushita, M; Kawaguchi, N; Morizane, T; Ohya, K; Kako, M
      Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases

      AUTOIMMUNITY
    8. Sabbagh, N; Brice, A; Marez, D; Durr, A; Legrand, M; Lo Guidice, JM; Destee, A; Agid, Y; Broly, F
      CYP2D6 polymorphism and Parkinson's disease susceptibility

      MOVEMENT DISORDERS
    9. Dalekos, GN; Wedemeyer, H; Obermayer-Straub, P; Kayser, A; Barut, A; Frank, H; Manns, MP
      Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronichepatitis C during alpha-interferon treatment

      JOURNAL OF HEPATOLOGY
    10. Favreau, LV; Palamanda, JR; Lin, CC; Nomeir, AA
      Improved reliability of the rapid microtiter plate assay using recombinantenzyme in predicting CYP2D6 inhibition in human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    11. Klein, R; Zanger, UM; Berg, T; Hopf, U; Berg, PA
      Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and navel peptide epitopes

      CLINICAL AND EXPERIMENTAL IMMUNOLOGY
    12. SHIN JG; KIM KA; YOON YR; CHA IJ; KIM YH; SHIN SG
      RAPID SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OFPAROXETINE IN HUMAN PLASMA

      Journal of chromatography B. Biomedical sciences and applications
    13. YOKOI T; KAMATAKI T
      GENETIC-POLYMORPHISM OF DRUG-METABOLIZING-ENZYMES - NEW MUTATIONS IN CYP2D6 AND CYP2A6 GENES IN JAPANESE

      Pharmaceutical research
    14. BOUSTEAD C; TABER H; IDLE JR; CHOLERTON S
      CYP2D6 GENOTYPE AND SMOKING-BEHAVIOR IN CIGARETTE SMOKERS

      Pharmacogenetics
    15. SHULMAN RW; OZDEMIR V
      PSYCHOTROPIC MEDICATIONS AND CYTOCHROME-P450 2D6 PHARMACOKINETIC CONSIDERATIONS IN THE ELDERLY

      Canadian journal of psychiatry
    16. SPROULE BA; OTTON SV; CHEUNG SW; ZHONG XH; ROMACH MK; SELLERS EM
      CYP2D6 INHIBITION IN PATIENTS TREATED WITH SERTRALINE

      Journal of clinical psychopharmacology
    17. MIHARA K; OTANI K; ISHIDA M; YASUI N; SUZUKI A; OHKUBO T; OSANAI T; KANEKO S; SUGAWARA K
      INCREASES IN PLASMA-CONCENTRATION OF M-CHLOROPHENYLPIPERAZINE, BUT NOT TRAZODONE, WITH LOW-DOSE HALOPERIDOL

      Therapeutic drug monitoring
    18. HADASOVA E; FRANKE G; ZSCHIESCHE M; CESKOVA E; ZELENKOVA O; SIEGMUND W
      DEBRISOQUINE 4-HYDROXYLATION AND SULFAMETHAZINE N-ACETYLATION IN PATIENTS WITH SCHIZOPHRENIA AND MAJOR DEPRESSION

      British journal of clinical pharmacology
    19. EICHELBAUM M; EVERT B
      INFLUENCE OF PHARMACOGENETICS ON DRUG DISPOSITION AND RESPONSE

      Clinical and experimental pharmacology and physiology
    20. DOMINGUEZ RA; KUMAR AM; CUA W
      LACK OF CHANGE IN FLUOXETINE AND NORFLUOXETINE KINETICS WHEN SWITCHING FROM FLUOXETINE TO PAROXETINE

      Journal of clinical psychopharmacology
    21. CARRILLO JA; DAHL ML; SVENSSON JO; ALM C; RODRIGUEZ I; BERTILSSON L
      DISPOSITION OF FLUVOXAMINE IN HUMANS IS DETERMINED BY THE POLYMORPHICCYP2D6 AND ALSO BY THE CYP1A2 ACTIVITY

      Clinical pharmacology and therapeutics
    22. MAUTZ DS; SHEN DD; NELSON WL
      REGIOSELECTIVITY AND ENANTIOSELECTIVITY OF METOPROLOL OXIDATION BY 2 VARIANTS OF CDNA-EXPRESSED P4502D6

      Pharmaceutical research
    23. PERSSON K; SJOSTROM S; SIGURDARDOTTIR I; MOLNAR V; HAMMARLUNDUDENAES M; RANE A
      PATIENT-CONTROLLED ANALGESIA (PCA) WITH CODEINE FOR POSTOPERATIVE PAIN RELIEF IN 10 EXTENSIVE METABOLIZERS AND ONE POOR METABOLIZER OF DEXTROMETHORPHAN

      British journal of clinical pharmacology
    24. LIU ZR; MORTIMER O; SMITH CAD; WOLF CR; RANE A
      EVIDENCE FOR A ROLE OF CYTOCHROME-P450 2D6 AND 3A4 IN ETHYLMORPHINE METABOLISM

      British journal of clinical pharmacology
    25. VONMOLTKE LL; GREENBLATT DJ; COURT MH; DUAN SX; HARMATZ JS; SHADER RI
      INHIBITION OF ALPRAZOLAM AND DESIPRAMINE HYDROXYLATION IN-VITRO BY PAROXETINE AND FLUVOXAMINE - COMPARISON WITH OTHER SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS

      Journal of clinical psychopharmacology
    26. PRESKORN SH; LANE RM
      SERTRALINE 50 MG DAILY - THE OPTIMAL DOSE IN THE TREATMENT OF DEPRESSION

      International clinical psychopharmacology
    27. YASUI N; OTANI K; KANEKO S; OHKUBO T; OSANAI T; ISHIDA M; MIHARA K; KONDO T; SUGAWARA K; FUKUSHIMA Y
      INHIBITION OF TRAZODONE METABOLISM BY THIORIDAZINE IN HUMANS

      Therapeutic drug monitoring
    28. KROEMER HK; EICHELBAUM M
      ITS THE GENES, STUPID - MOLECULAR-BASES AND CLINICAL CONSEQUENCES OF GENETIC CYTOCHROME-P450 2D6 POLYMORPHISM

      Life sciences
    29. MA Y; PEAKMAN M; LOBOYEO A; WEN L; LENZI M; GAKEN J; FARZANEH F; MIELIVERGANI G; BIANCHI FB; VERGANI D
      DIFFERENCES IN IMMUNE RECOGNITION OF CYTOCHROME P4502D6 BY LIVER-KIDNEY MICROSOMAL (LKM) ANTIBODY IN AUTOIMMUNE HEPATITIS AND CHRONIC HEPATITIS-C VIRUS-INFECTION

      Clinical and experimental immunology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 01:02:16